USA TODAY hears from experts who see GLP-1 drugs as only one part of diabetes care and point to continuous glucose monitors as a useful addition.
Recap by typeshit. Full story at USA TODAY on MSN.
A short Facebook share with no context on who used the peptides, where it happened or what followed.
Benzinga notes a 1.89% after-hours gain for Lilly stock, with Novo Nordisk also tagged. No further detail on what drove the move.
Mikhail Varshavski tells Fox News why protein matters, especially for GLP-1 users. He has a paid partnership with Quest Nutrition.
2:07:50
A live Q&A session covering GLP-1 drugs including Zepbound, Wegovy and Foundayo, with the host taking questions from viewers.
BiopharmIQ also notes TRIUMPH-5, which pits retatrutide directly against tirzepatide, is still running. That sets the timeline for a possible approval filing.
PHL17 shares findings that people on Ozempic and similar drugs are cutting alcohol spending at bars, restaurants and home.
Loading…